In patients with moderate peripheral artery disease, use of GLP-1 RAs increases the likelihood of more favorable cardiovascular and major limb outcomes.

Among older patients with diabetes, glucagon-like peptide 1 receptor agonists were associated with an increased risk for ...

A consensus statement from the Society for Perioperative Assessment and Quality Improvement recommends patients should ...

GLP-1 RAs are associated with a significant decrease in apnea-hypopnea index among patients with moderate to severe OSA and without diabetes.

Compounded vs non-compounded GLP-1 RA drug products are associated with an increased risk for adverse events such as nausea and diarrhea.

For patients with diabetes, exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with an increased ...

GLP-1 agonists may help reduce acetazolamide dosage in patients with idiopathic intracranial hypertension without changing clinical outcome.

such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) originally developed for type 2 diabetes. Liraglutide (Saxenda; Novo Nordisk), semaglutide (Wegovy; Novo Nordisk), and tirzepatide ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have revolutionized the management of metabolic diseases, offering substantial benefits in glycemic control, weight reduction, cardiovascular ...

Protective association seen between GLP-1 receptor agonist use and colon and rectal cancers in adults with obesity and diabetes.

The following is a summary of “Association of Glucagon-like Peptide-1 Receptor Agonists with Optic Nerve and Retinal Adverse ...